189 results on '"Huang, Deren"'
Search Results
2. Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial
3. Safety and efficacy of pioglitazone for the delay of cognitive impairment in people at risk of Alzheimer's disease (TOMMORROW): a prognostic biomarker study and a phase 3, randomised, double-blind, placebo-controlled trial
4. Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension
5. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study
6. Ublituximab, a Novel, Glycoengineered Anti-CD20 Monoclonal Antibody (mAb), Demonstrates Enhanced Antibody-Dependent Cellular Cytotoxicity (ADCC) Relative to Other Anti-CD20 mAbs (P7-3.011)
7. Ublituximab Efficacy in Treatment-Naive Participants With Relapsing Multiple Sclerosis in the Phase 3 ULTIMATE I and II Studies (P6-3.015)
8. Dimethyl Fumarate and Monomethyl Fumarate Promote Post-Ischemic Recovery in Mice
9. Natalizumab-treated patients at high risk for PML persistently excrete JC polyomavirus
10. Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis
11. Non-MHC Genetic Polymorphisms in Human Autoimmune Myasthenia Gravis
12. Challenges in randomized controlled trials and emerging multiple sclerosis therapeutics
13. Relapse Rate and Time to First Relapse Were Improved With Ublituximab vs Teriflunomide in the Phase 3 ULTIMATE I and ULTIMATE II Studies in Patients With Relapsing Multiple Sclerosis (RMS) (P1-1.Virtual)
14. Infusion-Related Reactions (IRRs) With Ublituximab in Patients With Relapsing Multiple Sclerosis (RMS): Post Hoc Analyses From the Phase 3 ULTIMATE I and II Studies (P6-4.010)
15. Ublituximab Treatment Is Associated With a Significant Proportion of Patients Achieving No Evidence of Disease Activity (NEDA): Results From the Ultimate I and Ultimate II Phase 3 Studies of Ublituximab vs Teriflunomide in Relapsing Multiple Sclerosis (RMS) (P6-4.005)
16. Disability Improvements With Ublituximab in Relapsing Multiple Sclerosis (RMS): Expanded Disability Status Scale (EDSS), 9-Hole Peg Test (9-HPT), and Timed 25-Foot Walk (T25FW) Evaluations From the Phase 3 ULTIMATE I and II Studies (P5-4.009)
17. Selective Sphingosine-1-Phosphate Receptor 1 Modulation Attenuates Experimental Intracerebral Hemorrhage
18. Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial
19. Fingolimod for the Treatment of Intracerebral Hemorrhage: A 2-Arm Proof-of-Concept Study
20. Update on PML: Lessons from the HIV uninfected and new insights in pathogenesis and treatment
21. Safety and efficacy of pioglitazone for the delay of cognitive impairment in people at risk of Alzheimer's disease (TOMMORROW): a prognostic biomarker study and a phase 3, randomised, double-blind, placebo-controlled trial
22. Efficacy and safety of ublituximab versus teriflunomide in relapsing multiple sclerosis: Results of the Phase 3 ULTIMATE I and II trials (4494)
23. CDS1 and promoter single nucleotide polymorphisms of the CTLA-4 gene in human myasthenia gravis
24. Baseline Demographics and Disease Characteristics from the ULTIMATE Phase III Trials Evaluating Ublituximab, a Novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Patients with Relapsing Multiple Sclerosis (4845)
25. Long-term Follow-up Results from the Phase 2 Multicenter Study of Ublituximab (UTX), a Novel Glycoengineered Anti-CD20 mAb, in Patients with RMS (1167)
26. Chemokine Receptor CXCR3: An Unexpected Enigma
27. Neurodegeneration and Neuroprotective Agents in Multiple Sclerosis
28. Progressive multifocal leukoencephalopathy in rheumatic diseases: Evolving clinical and pathologic patterns of disease
29. An Analysis of CTLA-4 and Proinflammatory Cytokine Genes in Wegenerʼs Granulomatosis
30. INFLUENCE OF CCR5, CCR5Δ32, RANTES AND MIP CHEMOKINES IN WEGENER'S GRANULOMATOSIS (WG).
31. TNF-α mediates SDF-1α-induced NF-κB activation and cytotoxic effects in primary astrocytes
32. Cytotoxic T-lymphocyte antigen-4 microsatellite polymorphism is associated with multiple myeloma
33. Chemokines and chemokine receptors in inflammation of the nervous system: manifold roles and exquisite regulation
34. Interleukin 6, tumour necrosis factor α, interleukin 1β and interleukin 1 receptor antagonist promoter or coding gene polymorphisms in multiple myeloma
35. Supplemental material for Patients transitioning from non-pegylated to pegylated interferon beta-1a have a low risk of new flu-like symptoms: ALLOW phase 3b trial results
36. Abnormal expression of CTLA-4 by T cells from patients with myasthenia gravis: effect of an AT-rich gene sequence
37. Antigen specific T cell derived B cell activation via CD40-CD40L interaction in Experimental Autoimmune Encephalomyelitis (EAE): 72
38. Pathogenesis: immunogenetic factors
39. Dinucleotide repeat expansion in the CTLA-4 gene leads to T cell hyper-reactivity via the CD28 pathway in myasthenia gravis
40. Patients transitioning from non-pegylated to pegylated interferon beta-1a have a low risk of new flu-like symptoms: ALLOW phase 3b trial results
41. Fingolimod enhances the efficacy of delayed alteplase administration in acute ischemic stroke by promoting anterograde reperfusion and retrograde collateral flow
42. Treatment satisfaction significantly improves in patients with multiple sclerosis switching from interferon beta therapy to peginterferon beta-1a every 2 weeks
43. Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension
44. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study
45. Treatment satisfaction significantly improves in patients with multiple sclerosis switching from interferon beta therapy to peginterferon beta-1a every 2 weeks
46. Polymorphisms at −174 and in the 3′ flanking region of interleukin-6 (IL-6) gene in patients with myasthenia gravis
47. Tumour necrosis factor-α polymorphism and secretion in myasthenia gravis
48. Markers in the promoter region of interleukin-10 (IL-10) gene in myasthenia gravis: implications of diverse effects of IL-10 in the pathogenesis of the disease
49. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
50. Treatment Satisfaction Increased over One Year When MS Patients Switched from an Interferon Beta Therapy to Peginterferon Beta-1a (P2.394)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.